Phase 2 Breast Cancer Trial, Recruiting NCT05228951 Sponsor: Shengjing Hospital Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT05228951
Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Women between 18 and 75 years old who are postmenopausal (either through surgical removal of the ovaries, being aged 60 or over, or having had no periods for 12 or more consecutive months with blood test results confirming menopause), OR premenopausal or perimenopausal women who are willing to receive a hormone-suppressing injection treatment during the study
  • Women who have been diagnosed with breast cancer confirmed by a tissue sample, where the cancer tests positive for estrogen receptor (ER above 10%), progesterone receptor (PR above 1%), and HER2 protein (confirmed by laboratory testing methods)
  • Women who have been diagnosed with stage II or stage III breast cancer (based on a standard cancer staging system) and are being treated for breast cancer for the first time
  • People whose general health and ability to carry out daily activities meets a minimum score on a standard medical scale (confirm with trial site)
  • People whose blood, liver, kidney, and heart function test results meet specific minimum levels set by the trial (confirm with trial site for exact values)
  • People who are able to undergo a tissue biopsy
  • People who are willing to participate, able to sign a consent form, and willing to attend follow-up appointments

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have already received any cancer treatment, such as chemotherapy, radiation therapy, targeted therapy, or hormone therapy
  • People who are currently receiving other cancer treatments at the same time
  • People who have cancer in both breasts, inflammatory breast cancer, or a form of breast cancer with no detectable breast lump
  • People who have stage IV (advanced/spread) breast cancer
  • People whose breast cancer has not been confirmed by a tissue sample
  • People who have had another type of cancer in the past 5 years (except for cervical cancer in situ that has been fully treated)
  • People who have serious problems with the functioning of the heart, liver, kidneys, or other major organs
  • People who have conditions that may affect the ability to take or absorb medication, such as difficulty swallowing, ongoing diarrhea, or a bowel blockage
  • People who have taken part in another clinical drug trial within the past 4 weeks
  • People with a known allergy to any of the study drugs, or a history of immune system disorders (including HIV, hepatitis C, active hepatitis B, other immune deficiency conditions, or a history of organ transplant)
  • People with a history of significant heart conditions, including heart rhythm problems requiring medication, heart attack, heart failure, or other heart disease considered unsuitable by the trial doctor
  • Women who are pregnant or breastfeeding, women of childbearing age who test positive for pregnancy at the start of the trial, or women of childbearing age who are unwilling to use effective contraception throughout the study
  • People with other serious ongoing health conditions — such as severe high blood pressure, severe diabetes, or active infections that cannot be controlled with medication — that could affect health or study participation
  • People with a diagnosed neurological or psychiatric condition, such as epilepsy or dementia

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 31 July 2026

Contact this trial

Principal Investigator: Cai-Gang Liu, PHD, Shengjing Hospital

Phone: +8618940256668

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shengjing Hospital
Registry
ClinicalTrials.gov
Start date
10 February 2022
Est. completion
31 December 2022

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Total pathological complete response (tpCR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov